Johnson & Johnson single shot coronavirus vaccine approved for use in EU
The Johnson and Johnson vaccine has proven to be effective in providing protection against severe Covid-19
Updated
The Johnson & Johnson jab. (Image: REUTERS)
Want the latest news straight to your inbox? Sign up for our free newsletterInvalid EmailSomething went wrong, please try again later.
Subscribe
When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice
The European Medicines Agency have today approved the usage of the Johnson & Johnson single shot coronavirus vaccine in Europe.
Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at JLABS @ Washington, DC. In this role, she is responsible for managing the
BLUE KNIGHT™ collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). BLUE KNIGHT™ focuses on addressing public-health threats and emerging infectious diseases by supporting companies with emerging science and technology solutions that aim to improve health security and responses. Rachel is responsible for the strategic direction, alliance management, and oversight of all operational activities related to the collaboration with BARDA, including managing the sourcing and selection of high potential companies for JLABS locations and leading a cross-departmental team to develop global educational programming.
Johnson & Johnson Campaign tackles rising AF challenge
The cardiac awareness raising campaign is being spearheaded by Arrythmia Alliance and Biosense Webster
‘Get Smart About AFIB’ is a new public health campaign developed to address the escalating epidemic of atrial fibrillation (AF), which has doubled in prevalence over the past decade and is predicted to rise by a further 70 per cent by 2030.
The campaign aims to generate awareness, improve knowledge and encourage better detection of AF that affects more than 40,000 people in Ireland older than 50 years.
The initiative is being spearheaded by Arrythmia Alliance and Biosense Webster, part of the Johnson & Johnson Family of Companies (J&J), to tackle the challenge of AF, now recognised as a major public health condition with high comorbidity, increased mortality and soaring healthcare costs. The campaign seeks to provide educational materials to doctors, both primary care providers and cardiologists, to support their work in